Cargando…

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

BACKGROUND: Patients with cancer are at high risk for severe coronavirus disease 2019 (COVID-19) infection. Knowledge regarding the efficacy of the messenger RNA (mRNA) vaccines in actively treated cancer patients is limited as they had been excluded from the pivotal studies of these vaccines. We ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, E., S. Fischer, R. Demmer-Steingruber, Nigg, S., Güsewell, S., Albrich, W.C., Rothermundt, C., Silzle, T., Kahlert, C.R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399124/ https://www.ncbi.nlm.nih.gov/pubmed/36156449 http://dx.doi.org/10.1016/j.esmoop.2022.100587

Ejemplares similares

In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms
por: Ayers, Emily, et al.
Publicado: (2023)

Pediatric hospital admissions, case severity, and length of hospital stay during the first 18 months of the COVID-19 pandemic in a tertiary children’s hospital in Switzerland
por: Bögli, Jasmin, et al.
Publicado: (2022)

Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis
por: Karakizlis, Hristos, et al.
Publicado: (2022)

Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms
por: Kobayashi, Mirei, et al.
Publicado: (2023)

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments
por: Piubelli, Chiara, et al.
Publicado: (2023)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
por: Liu, Qiaofei, et al.
Publicado: (2023)

Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination
por: van der Lee, Saskia, et al.
Publicado: (2018)

The Kinetics of Humoral and Cellular Responses after the Booster Dose of COVID-19 Vaccine in Inflammatory Arthritis Patients
por: Wroński, Jakub, et al.
Publicado: (2023)

P1534: MRNA-1273 SARS-COV-2 VACCINE IN RECENTLY TRANSPLANTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: CELLULAR AND HUMORAL IMMUNE RESPONSES AND BOOSTER EFFECT
por: Albiol, Nil, et al.
Publicado: (2023)

Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice
por: Gao, Feng-Xia, et al.
Publicado: (2022)

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
por: Méndez, Constanza, et al.
Publicado: (2023)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study
por: Yang, Lu M., et al.
Publicado: (2022)

Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
por: Pérez-Flores, Isabel, et al.
Publicado: (2023)

mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect
por: Albiol, Nil, et al.
Publicado: (2023)

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients
por: Schmidt, Tina, et al.
Publicado: (2021)

Proceedings: Humoral immunity in human lung neoplasms.
por: Dawson, M., et al.
Publicado: (1975)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
por: Nishikubo, Masashi, et al.
Publicado: (2023)

Management of Solid-pseudopapillary Neoplasms of the Pancreas: a Comparison with Standard Pancreatic Neoplasms
por: de Castro, S. M. M., et al.
Publicado: (2007)

The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review
por: Hartmann, Julia E., et al.
Publicado: (2021)

Solid Bioneedle-Delivered Influenza Vaccines Are Highly Thermostable and Induce Both Humoral and Cellular Immune Responses
por: Soema, Peter C., et al.
Publicado: (2014)

Acute respiratory distress syndrome during the COVID-19 pandemic: not only SARS-CoV-2
por: Meyer Sauteur, P.M., et al.
Publicado: (2021)

Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
por: Atanasio, A., et al.
Publicado: (2023)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Pathology of Lung Rejection: Cellular and Humoral Mediated
por: Roden, Anja C., et al.
Publicado: (2018)

Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
por: Abravanel, Florence, et al.
Publicado: (2022)

Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections
por: Desmecht, Salomé, et al.
Publicado: (2022)

P1053: ALBUMIN AND C-REACTIVE PROTEIN PROVIDE PROGNOSTIC INFORMATION INDEPENDENTLY FROM MIPSS70 IN OVERT MYELOFIBROSIS. A RETROSPECTIVE STUDY.
por: Messerich, N.-M., et al.
Publicado: (2022)

Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
por: Patyna, Sammy, et al.
Publicado: (2022)

Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?
por: Beilhack, Georg, et al.
Publicado: (2022)

Antibiotic-resistant pathogens in different patient settings and identification of surveillance gaps in Switzerland – a systematic review
por: Fulchini, R., et al.
Publicado: (2019)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
por: Mairhofer, Mario, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
por: Lyski, Zoe L., et al.
Publicado: (2022)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients
por: Kwiatkowska, Ewa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ino41vhlo1dgsevij6tpl9b2e8